June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Bevacizumab and Ranibizumab in the treatment of diabetic macular oedema: Can results from clinical trials be reproduced in the National Health Service?
Author Affiliations & Notes
  • Nicholas Brennan
    Ophthalmology, Hillingdon Hospital, London, United Kingdom
    Ophthalmology, Institute of ophthalmology, moorfields eye hospital, London, United Kingdom
  • Maxwell Treacy
    Ophthalmology, Institute of ophthalmology, moorfields eye hospital, London, United Kingdom
    Ophthalmology, Royal Victoria Eye and Ear Hospital, Adelaide Road,, Dublin, Ireland
  • Conor Ramsden
    Ophthalmology, Hillingdon Hospital, London, United Kingdom
    Ophthalmology, Institute of ophthalmology, moorfields eye hospital, London, United Kingdom
  • Nicholas Lee
    Ophthalmology, Hillingdon Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Nicholas Brennan, None; Maxwell Treacy, None; Conor Ramsden, None; Nicholas Lee, novartis (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2391. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nicholas Brennan, Maxwell Treacy, Conor Ramsden, Nicholas Lee; Bevacizumab and Ranibizumab in the treatment of diabetic macular oedema: Can results from clinical trials be reproduced in the National Health Service?. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2391.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To assess the reproducibility of clinical trials on the treatment of DMO with anti-VEGF modalities in the National Health Service in the United Kingdom.

Methods: A retrospective case note analysis of patients treated with Bevacizumab or Ranibizumab for DMO at two west London hospitals. Minimum 12month follow up. Treated between 2008-2012. Outcome measures: 1.Difference in ETDRS best-corrected visual acuity (BCVA) at Baseline and 12 months. 2.Mean change in BCVA 3.Proportion gaining at least 15 letters, 0-15 letters and 0-10 letters 4.Change in central macular thickness.

Results: 91 patients were treated with Bevacizumab and 15 with Ranibizumab that met the diagnostic and follow up inclusion criteria. The Bevacizumab group showed 7 EDTRS letter gain with a mean change in CMT of -104 µm. 70% of patients responded to treatment with 22% gaining ≥ 15 letters and 48.4% gaining between 0-10 letters. In the Ranibizumab group a 4 EDTRS letter gain with a mean change in CMT of -64 µm was obtained. 40% of patients responded to treatment with 13% gaining ≥ 15 letters and 27% gaining 0-10 letters. There were no adverse events reported in either group.

Conclusions: Although both anti-vegf modalities improved visual acuity the degree of improvement was inferior to that seen in the recently published clinical trials. In our study the results for Bevacizumab were superior to Ranibizumab.

Keywords: 498 diabetes • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×